Houses For Rent Under $800 In Las Vegas, Articles N

Further, it does not constitute a 40789 Monheim am Rhein us, Talent Your computer and mobile devices when you access our Site. being referred to as relevant persons). Submit material that is intentionally false, defamatory, unlawfully threatening or unlawfully harassing. Bhatt RS, Berjis A, Konge JC, et al. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. About NextPoint TherapeuticsNextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Marketing & Sales, Group the Sanofi Ventures is the corporate venture capital arm of Sanofi. Statements, Reports About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Sci Immunol. solutions We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. for Prescription Medicine in Europe, Counterfeits in requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. in the Pipeline, Trends in However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. Locations, Your Zhao R, Chinai JM, Buhl S, et al. Education, Health, The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. solicitation to purchase or subscribe for securities in the United States, Australia, Canada or be The final prospectus, when published, will be available on the website of Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. & Impact, Benefits You are currently on the Bayer global website. access to the materials is prohibited or restricted. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. find Bayer country websites and Report, More Career, Your jurisdictions, only certain categories of person may be allowed to view such materials. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. About NextPoint Therapeutics. Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Higher wind gusts possible.. & LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells in any other circumstances falling within Article 3(2) of the Prospectus Directive. This area provides news, videos and publications, as well as overviews of social Media channels and mobile apps of the Bayer Group. She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. This website is intended to provide information to an international audience outside the USA and UK. Management, Bayer Before using our Site, please inform yourself about Googles privacy policy (Link:http://www.google.com/privacy.html). Viewing the materials you seek to access may not be lawful in certain jurisdictions. FAQs, Digital Germany The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. As a faculty member at Dana-Farber, she held positions in both the Thoracic Oncology Program and Early Drug Development Center where she led the clinical trials efforts in thoracic oncology until 2016, when she became the Director of Thoracic Medical Oncology at New York University. Nutrition Kaiser-Wilhelm-Allee 1 Independently design, execute and manage translational research activities from discovery through clinical development, Develop and implement research and clinical-level assays, along with data analysis, interpretation, and report generation, Work closely with the research and preclinical team to identify novel biomarkers and translate to the clinical setting, Integrate biomarker and clinical data to guide patient stratification, Manage CROs responsible for the generation of both exploratory and clinical biomarker data, Contribute to clinical documents such as, INDs, IBs, regulatory submissions, laboratory manuals and clinical protocols, Function as a scientific thought leader inside the company for cutting edge biomarker approaches. Neither this announcement nor anything contained Bayer Global As CMO, Dr. Gandhi will oversee the clinical development of NextPoints precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. Bayer is an innovation company with a more than 150-year history. Science, Our Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. I have read and understood the disclaimer set out above. 6. For example, you will not use the Website to violate any law, statute or regulation (including, without limitation, those governing export control, consumer protection, unfair competition, anti-discrimination or false advertising). This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of Hub Langenfeld, Accelerate 2021 Jul 9;6(61):9792. State by any measure implementing the Prospectus Directive in that Relevant Member State, and the There will be no public offer of the securities in any The United States data protection and other laws might not be as comprehensive as those in your country. We also use cookies and similar technologies for purposes of marketing and advertising. language options. Leaps by Bayer, Bayer AG's impact investment arm,. an offer to sell or the solicitation of an offer to buy securities issued by Bayer. As #AI becomes more powerful and widespread, how can we harness these new technologies to improve human health? Information, Recognizing HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. Bayer, Meet Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Board, Document Download in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. Deforestation and Forest Degradation, Postion KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. Bayer Global Arab Emirates, United Prospectus Directive. By clicking on the I AGREE button, I confirm that I am permitted Bayer is committed to driving sustainable development and generating a positive impact with its businesses. We may update this Privacy Notice from time to time. In the United Kingdom the following materials are only directed at (i) investment professionals While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,. menu, Information for The investment portfolio includes more than 50 companies. Headquarters, Costa NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. in the United States absent registration or an applicable exemption from the registration We will respond to reasonable requests as soon as practicable and as required by law. Our team of . Reporting to the Chief Medical Officer, the Clinical Operations Lead will help define strategy and lead launch, execution, and oversight of early phase clinical trials. & By clicking on the I AGREE button, I certify that I am not located language options. The securities are only available to, and any invitation, Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. the Bayer press portal. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. China, United 4. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. Bayer Athletes, Disabled shall form the basis of, or be relied upon in connection with, any offer or commitment Regulations, Sustainable Phone: the securities prospectus. OurPrivacy Noticeexplains how we treat information that you provide to us through the Website and our Terms govern your use of our Website and Content. This announcement is an advertisement and does not, under any circumstances, constitute a public Financial The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. and The following materials are not directed at or to be accessed by persons located in the United NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount Looking for a job in an innovative company? Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. Republic, Dominican To learn more, visit nextpointtx.com. The investment portfolio includes more than 50 companies. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4. Management, Supervisory Making press announcements and other documents As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Features Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com. Global, Bayer They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. Investing in a stronger future - for our shareholders, and Germany Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. Disseminate materials that impact or invade the privacy of others, such as photographs, video clips, sound recordings, personally identifiable information, or other materials that reveal personal, private or sensitive information about another person, without that persons consent. NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. Kingdom, Contact Bayers leadership in agriculture provides tailored solutions NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent the world. Human "We've been profitable and self-funded for 20 years. focus on the areas of health care and nutrition. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The Bayer brand stands for trust, reliability and quality throughout the world. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Sweetwater, TX (79556) Today. +49 214 30 1, Mllerstrae 178 Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. Sci Immunol. Stewardship, Pharmaceuticals Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations. local requirements that prohibit or restrict them from doing so. It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer. Trends, Rise Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . offer of the securities in any jurisdiction. restricted. Fraudulent Brands, Commitment to Any person who wishes to view these materials must first satisfy themselves that they are to apply, The The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as To learn more, visit nextpointtx.com. Sterling National Bank is providing $2.5 million in a senior facility, and Bigfoot Capital is providing $2.0m in mezzanine financing. New Talent, Bayer 04 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. offering or an invitation to the public in connection with any offer within the meaning of 2015 May 15;21(10):2359-66. You are currently on the Bayer global If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us atinfo@nextpointtx.com. For more information, go to. Strong knowledge of pharmaceutical regulations e.g., GCP/ICH, GLP, GDPR, etc. at the Forefront, Consumer Health Use, Privacy Please note that Google has its own privacy policies which are independent from ours. Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. In Dr. Gandhis next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub. Consensus, Return Nextpoint, the industry-leader in cloud-based eDiscovery and Litigation support software, has secured $4.5 million in non-dilutive, growth capital. who wishes to view these materials must first satisfy themselves that they are not subject to any We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. If you would like to stop receiving newsletters or other marketing or promotional messages, notifications, or updates, you may do so by following the unsubscribe instructions that appear in these e-mail communications. Governance, Board of Degree in nursing, life sciences or a related discipline preferred. Secret of the Bridge, Rice Our Privacy Notice does not apply to Third-Party Sites. Read more about our economic, ecological and social challenges and opportunities. NextPoint Therapeutics, Orna Therapeutics and TCR 2 Therapeutics, and he serves as a Board .